Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Directorate Change

25th Nov 2009 09:21

RNS Number : 0499D
Akers Biosciences, Inc.
25 November 2009
 

For immediate release: 25 November 2009

Akers Biosciences Inc.

("ABI" or the "Company")

Directorate Change

Akers Biosciences, Inc (AIM:AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, regrets to announce the sudden death of Daniel L. Seckinger JR, MD., a non-executive Director of the Company. Dr Seckinger passed away at his home on Friday 20 November 2009

Dr Seckinger, a former President of the College of American Pathologists, and a Clinical Professor of Pathology at the University of Miami Medical School, had resided on the ABI board of directors since 1994.

Dr Raymond F. Akers, Executive Vice Chairman and Founder of ABI, commented,

"Dan has been my good friend and colleague for nearly twenty years and was an integral part of the Company's development. A titan of our industry, I was fortunate to have worked with him."

Enquiries:

Thomas A. Nicolette

President and CEO

Tel. +1 856 848 8698

Alasdair Younie

Arbuthnot Securities Limited

Tel. +44 (0)20 7012 2000

Ben Simons

M: Communications

Tel. +44 (0)20 7920 2340

About Akers Biosciences

Akers Biosciences, Inc. develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. ABI has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAKELBLKFBLFBB

Related Shares:

AKR.L
FTSE 100 Latest
Value8,809.74
Change53.53